Normal view MARC view ISBD view

Prevalence, Awareness, Treatment, and Control of Hypertension among Chinese First-Generation Migrants and Italians in Prato, Italy: The CHIP Study. [electronic resource]

By:

Modesti, Pietro A

Contributor(s):

Publication details: International journal of hypertension 2017Description: 6402085 p. digitalISSN:

2090-0384

Online resources:

Available from publisher's website

In: International journal of hypertension vol. 2017

Tags from this library: No tags from this library for this title. Log in to add tags.

Average rating: 0.0 (0 votes)

No physical items for this record

Publication Type: Journal Article

There are no comments on this title.

to post a comment.

Back to results

1 Antineutrophil cytoplasmic autoantibody-associated small-vessel vasculitis.
by Kallenberg, Cees Gm
2 Key advances in the clinical approach to ANCA-associated vasculitis.
by Kallenberg, Cees G M
3 The diagnosis and classification of microscopic polyangiitis.
by Kallenberg, Cees G M
4 Anti-C1q autoantibodies.
by Kallenberg, Cees G M
5 Pathophysiology of ANCA-associated small vessel vasculitis.
by Kallenberg, Cees G M
6 Opponent's comments.
by Kallenberg, Cees G M
7 Usefulness of antineutrophil cytoplasmic autoantibodies in diagnosing and managing systemic vasculitis.
by Kallenberg, Cees G M
8 Pathogenesis and treatment of ANCA-associated vasculitides.
by Kallenberg, Cees G M
9 Dying neutrophils in ANCA-associated vasculitis: good or bad guys?
by Kallenberg, Cees G M
10 Churg-Strauss syndrome: just one disease entity?
by Kallenberg, Cees G M
11 The last classification of vasculitis.
by Kallenberg, Cees G M
12 Etiopathogenesis of systemic autoimmune diseases.
by Kallenberg, Cees G M
13 Pathogenesis of ANCA-associated vasculitis, an update.
by Kallenberg, Cees G M
14 Pathogenesis of ANCA-associated vasculitides.
by Kallenberg, Cees G M
15 Advances in pathogenesis and treatment of ANCA-associated vasculitis.
by Kallenberg, Cees G M
16 Pro: Cyclophosphamide in lupus nephritis.
by Kallenberg, Cees G M
17 What is the evidence for prophylactic antibiotic treatment in patients with systemic vasculitides?
by Kallenberg, Cees G M
18 Could we abandon cyclophosphamide in systemic vasculitis and lupus nephritis?
by Kallenberg, Cees G M
19 Renal vasculitis in 2012: reclassification and the introduction of biologicals.
by Kallenberg, Cees G M
20 Treatment of ANCA-associated vasculitis, where to go?
by Kallenberg, Cees G M